The Vigabatrin REMS Program is called for by the FDA to ensure informed risk-benefit choices before launching therapy, and to guarantee appropriate use vigabatrin while patients are treated. It is not possible for your healthcare provider to know when vision loss will occur.
It is advised that your healthcare provider examination your (or your child's) vision before or within 4 weeks after starting SABRIL and at least every 3 months throughout therapy up until SABRIL is stopped. If you or your child have any type of side impact that troubles you or that does not go away, inform your healthcare company.
Tell your doctor if you are expectant or plan to get pregnant. If vision testing can not be done, your doctor might continue recommending SABRIL, however will certainly not have the ability to watch for any type of vision loss. If vision tests are refrained from doing consistently, your healthcare provider may stop prescribing SABRIL for you (or your child).